Precision Peptide develops needle-free tirzepatide transdermal patch in U.S

• The Precision Peptide Company is developing a needle-free tirzepatide transdermal patch in the U.S. as an expansion of its delivery platform.
• Program targets room-temperature stability, aiming to remove refrigeration needs tied to most injectable tirzepatide products.
• Development work is being conducted in the U.S., with manufacturing also planned in the U.S. to meet FDA standards.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608190700NEWSFILECNPR____20260819_310329_1) on August 19, 2026, and is solely responsible for the information contained therein.